Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0
|
作者：
Narezkina, Anna [1 ]
Akhter, Nausheen [2 ]
Lu, Xiaoxiao [3 ]
Emond, Bruno [4 ]
Huang, Qing [3 ]
Panjabi, Sumeet [3 ]
Hilts, Annalise [4 ]
Lu, Stephanie [5 ]
Lafeuille, Helene [4 ]
Lafeuille, Marie-Helene [4 ]
Choi, Michael [6 ]
机构：
[1] Univ Calif San Diego Hlth, San Diego, CA USA
[2] Northwestern Med, Chicago, IL USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Anal Grp Inc, Montreal, PQ, Canada
[5] Anal Grp Inc, Menlo Pk, CA USA
[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-390
引用
收藏
页码：S276 / S277
页数：2
相关论文
共 50 条
  • [11] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Collins, James
    Stump, Sarah E.
    Heiling, Hillary
    Muir, Michele
    Deal, Allison
    Proco, Darrian
    Nguyen, Catharine
    Cozad, Monica
    Mato, Anthony
    Coombs, Catherine C.
    Muluneh, Benyam
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1823 - 1830
  • [12] Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
    Pinilla-Ibarz, Javier
    Xue, Mei
    Wu, Elizabeth
    Esselman, Kaitlyn
    Furnback, Wesley
    Challagulla, Swetha
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S358 - S359
  • [13] Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
    O'Brien, Susan
    Hillmen, Peter
    Coutre, Steven
    Barr, Paul M.
    Fraser, Graeme
    Tedeschi, Alessandra
    Burger, Jan A.
    Dilhuydy, Marie-Sarah
    Hess, Georg
    Moreno, Carol
    Cramer, Paula
    Liu, Emily
    Chang, Stephen
    Vermeulen, Jessica
    Styles, Lori
    Howes, Angela
    James, Danelle F.
    Patel, Kalpesh
    Graef, Thorsten
    Valentino, Rudolph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10) : 648 - +
  • [14] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [15] Real-World Clinical Outcomes of First-Line (1L) Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shadman, Mazyar
    Karve, Sudeep
    Abbazio, Christopher
    Majd, Zahra
    Bacchus, Shaffee
    Saifan, Chadi
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Emond, Bruno
    Srivastava, Bhavini P.
    Stephens, Deborah M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S352 - S352
  • [16] Comparison of Time to Next Treatment Between Patients With Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib Overall and in a Subgroup With High-Risk Characteristics
    Jacobs, Ryan
    Levy, Moshe Y.
    Yazbeck, Victor
    Lafeuille, Marie-Helene
    Emond, Bruno
    Gogna, Priyanka
    Maegawa, Rodrigo
    Qureshi, Zaina P.
    Ferrajoli, Alessandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S351 - S351
  • [17] Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
    Archibald, William J.
    Rabe, Kari G.
    Kabat, Brian F.
    Herrmann, Joerg
    Ding, Wei
    Kay, Neil E.
    Kenderian, Saad S.
    Muchtar, Eli
    Leis, Jose F.
    Wang, Yucai
    Chanan-Khan, Asher A.
    Schwager, Susan M.
    Koehler, Amber B.
    Fonder, Amie L.
    Slager, Susan L.
    Shanafelt, Tait D.
    Call, Timothy G.
    Parikh, Sameer A.
    ANNALS OF HEMATOLOGY, 2021, 100 (01) : 143 - 155
  • [18] Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
    William J. Archibald
    Kari G. Rabe
    Brian F. Kabat
    Joerg Herrmann
    Wei Ding
    Neil E. Kay
    Saad S. Kenderian
    Eli Muchtar
    Jose F. Leis
    Yucai Wang
    Asher A. Chanan-Khan
    Susan M. Schwager
    Amber B. Koehler
    Amie L. Fonder
    Susan L. Slager
    Tait D. Shanafelt
    Timothy G. Call
    Sameer A. Parikh
    Annals of Hematology, 2021, 100 : 143 - 155
  • [19] Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed
    Laliberte, Francois
    ONCOLOGIST, 2024, 29 (03) : E360 - E371
  • [20] Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Jacobs, Ryan
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 2073 - 2084
12345